Clinical Trials
3 trialsNCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05482074 2024-01-19
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04633902 2022-12-06
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Phase 2 Unknown